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Introduction
Cardiac function depends on the tightly coordinated activity of voltage-gated Na + channels (Na v ) that are responsible for generating the action potential (AP) upstroke in response to an external stimulus. 1, 2 Importantly, Na v normally inactivate almost as quickly as they activate, a requirement for the cell membrane to repolarize in preparation for the next stimulus/heartbeat.
While voltage-dependent inactivation rapidly turns off most Na v current (I Na ), a small persistent ("late") component (I Na,L ) is apparent even under normal conditions. 3 Aberrant I Na,L is directly linked with increased susceptibility to arrhythmia and dysfunction in cardiac disease. 4, 5 For example, increased I Na,L is present in congenital gain-of-function Na v channelopathies (e.g. long QT 3), as well as in common forms of acquired disease (e.g. heart failure), and has been implicated in AP prolongation, abnormal ion homeostasis and arrhythmia. 3, [6] [7] [8] Drugs that specifically target I Na,L are emerging as viable therapeutic agents to reduce arrhythmia burden in cardiac disease patients. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] A key feature of these agents is their selectivity for I Na,L over peak current. 20 Thus, it is important to understand the molecular pathways for regulating I Na,L without altering other critical components of Na v 1.5 current (availability, recovery kinetics, etc.).
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mechanism remains under investigation, several potential sites for CaMKII phosphorylation have been identified in the DI-DII linker of Na v 1.5, the predominant cardiac Na v alpha subunit. pathways to selectively regulate I Na,L has stalled due to lack of relevant animal models.
In an effort to identify the molecular basis for CaMKII-dependent regulation of Na v 1.5 and cell excitability in vivo, we generated two novel Scn5a knock-in mouse models: 1) the S571E mouse that substitutes a phosphomimetic glutamic acid for the serine at position 571; and 2) the S571A mouse that lacks the phosphorylation site due to replacement of the serine with an alanine. Using these new animal models, we report that Ser571 is essential for targeted regulation of I Na,L , cell excitability and heart function in response to stress (pressure-overload induced heart failure). Furthermore, we observe that ablation of the Ser571 site mitigates maladaptive electrical and mechanical remodeling observed in the failing heart. Based on these findings, we propose that Ser571 serves as a binary molecular switch for CaMKII-dependent activation of I Na,L in vivo. Importantly, Ser571-dependent regulation is selective for I Na,L without affecting other channel properties that may have deleterious consequences for cardiac function.
We anticipate that this molecular pathway may yield new therapeutic avenues for reducing or neonatal cardiomyocytes. Thus, this field while potentially fruitful in the searc c ch h h fo fo for r r ne ne new w w pathways to selectively regulate I Na,L I I has stalled due to lack of relevant animal models. f I I In n n an an an effo or ort t t to identify the molecular basi si is s s fo fo for CaMKII-depende e ent nt nt regulation of Na v 1.5
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Methods

Animals
Scn5a S571E and S571A knock-in mice were generated (genOway) in C57/Bl6 background using a Flp-mediated strategy to remove neomyocin selection cassette. Resulting animals expressed either the S571E or S571A point mutation (Figure 1 ). Experiments were performed in 2-month-old male mice. Animals were euthanized using CO 2 and cervical dislocation followed by collection of tissue or cell isolation. Studies were conducted in accordance with the , 1 1 I I I Na I I r r rec ec ecor or ordi di ding ng ngs s s we e were re re p p per er erfo fo form rm rmed ed ed o o on n n fr fr fres es eshl hl hly is is isol ol olat at ated ed ed ( ( (<1 <1 <1 h h h i i in n n cu c cult lt ltur r ure) e) e) m m myo o yocy c cyte te tes s s CdCl2 (0.1), glucose (11), CsCl (132.5) and Hepes (20) ; pH was maintained at 7.4 with CsOH.
Only cells with membrane resistance greater than 1 G were used. Appropriate whole cell capacitance and series resistance compensation ( 60%) was applied. Resulting currents were blocked with tetrodotoxin (TTX) to verify isolation of I Na (Supplemental Figure 1 ). APs were recorded using the perforated (amphotericin B) patch-clamp technique at room temperature in
Tyrode's solution (bath). The pipette solution contained (in mM): potassium aspartate (130), NaCl (10), HEPES (10), CaCl 2 (0.04), MgATP (2), phosphocreatine (7), NaGTP (0.1), and 240 μg/mL amphotericin B. The pH was adjusted to 7.2 with KOH. APs were evoked by brief current pulses 1.5-4 pA, 0.5-1 ms. In all cases, the electrophysiologist was blinded to animal genotype.
Mouse heart failure model with proximal aortic banding
Transaortic constriction was performed to induce pressure overload conditions in adult male mice. 32 Mice were anesthetized (isofluorane, 2.5%), intubated, and placed on a respirator (120 breaths min 1, 0.1 mL tidal volume). The aorta was exposed via a midline sternotomy and a 6.0 Prolene suture was placed around the aorta distal to the brachiocephalic artery. The suture was tightened around a blunted 27-gauge needle placed next to the aorta, the needle was removed, and the chest was closed. A group of sex-and age-matched sham mice underwent the same procedure with the suture step omitted as a control. Echocardiography was performed before surgery and at regular intervals for six weeks following surgery to assess cardiac function using the Vevo 2100 (Visualsonics). The MS-400 transducer was used in the short axis M-mode to assess heart function and contractile features. Mice were sacrificed (2% Avertin, 20 L/g, I.P.)
via rapid thoracotomy at 6 weeks post-surgery (TAC or sham). Hearts, lung tissue, and right tibias were gathered from each mouse for further analysis.
genotype.
Tran n nsa sa saor or orti ti tic c c co co c ns s str tr tric i i tion was performed to induc ce e e pr pr pressure overlo f f ad con n ndi di d tions in adult male m m mic ce c . 32 Mice w w wer e e e e an an anes s sth th thet et etiz z zed ed ed ( ( (is is isof of oflu lu luo oran ne e, e 2 2.5%) %) %), in n ntu tu tuba ba bate e ed, a a and nd nd p pla la lace ed on on on a a a r r res es e pi pi p ra ra at t tor r r Additional methods are provided in online only Data Supplement.
Results
Generation of S571E/A knock-in mice to test in vivo role of Ser571
Functional in vitro studies have demonstrated a role for CaMKII-dependent phosphorylation at Ser571 in regulating Na v 1.5 ( Figure 1A) . 22, 26, 29 To test the central hypothesis that phosphorylation of Na v 1.5 at Ser571 is essential for CaMKII-dependent changes in I Na,L and channel kinetics in vivo, two novel Scn5a knock-in mouse models were generated: 1) an S571E mouse, where the serine at position 571 is replaced with a glutamic acid (phosphomimetic); and 2) an S571A mouse, where the serine is replaced with an alanine to eliminate the CaMKII phosphorylation site ( Figure 1B) . While phospho-Na v 1.5(Ser571) was not detectable in S571A
or S571E lysates (phospho-epitope eliminated by either mutation), protein expression levels and cellular localization of Na v 1.5 were normal in S571E and S571A myocytes compared to WT at baseline. Furthermore, there were no differences in levels or localization of related associated proteins CaMKII, IV -spectrin, or ankyrin-G 22, 26, 33 ( Figure 1C-G) . Expression/localization of the intercalated disc protein N-cadherin was also normal in S571E and S571A myocytes ( Figure   1E -G). Histological examination of S571E and S571A hearts at baseline revealed no evidence of overt structural changes (e.g. fibrosis) compared to WT at baseline (data not shown).
Echocardiography revealed small but significant LV dilation in S571E animals at baseline and small but significant decreases in ejection fraction and fraction shortening in both S571E and S571A animals without differences in other features ( Table 1 ).
Phosphorylation at S571 selectively regulates I Na,L and cell membrane excitability
Disruption of spectrin/CaMKII interaction reduces Na v 1.5 phosphorylation at Ser571 and alters Na v 1.5 activity and cell excitability. 26 To assess the specific role of Ser571 in CaMKIIdependent regulation of Na v 1.5 at baseline, electrophysiology experiments were performed on isolated, adult ventricular WT, S571E, and S571A myocytes (Figure 2) . Whole cell I Na measurements showed a significant increase (~two-fold) in S571E I Na,L without any change in peak current compared to WT at baseline (Figure 2A-B, Supplemental Figure 1 ). In contrast, S571A myocytes displayed a significant reduction in I Na,L despite an increase in peak current compared to WT (Figure 2A-B, Supplemental Figure 1) . Surprisingly, no differences were observed in steady-state inactivation or recovery from inactivation in S571E or S571A compared to WT (Figure 2C-D Action potentials (APs) were measured in isolated adult ventricular WT, S571E, and Na v 1.5 activity and cell excitability. af af afte te terd rd rdep ep epol ol olar ar ariz i izat at atio io ions ns ns e e eve e ven n n in in in S S S57 57 571E 1E 1E ( ( (da da data ta ta n n not ot ot s s sho ho hown n wn) ) ), h h hig ig igh h h do do dose se se i i is s sop op opro ro rote te tere re reno no nol l l el el elic ic icit it ited ed ed f f fre re requuen en ent t t mice. S571E mice demonstrated significant prolongation of rate corrected QT interval (QTc) compared to WT, in agreement with measured differences in I Na,L and APD ( Figure 4A -B). indicating that hypertrophy occurs independent of phosphorylation at Ser571. However, ejection fraction, fractional shortening and LV chamber diameter following TAC showed improvement in S571A compared to WT or S571E animals ( Figure 5F -J). For example, while ejection fraction decreased by over 40% in both WT and S571E animals following 6 weeks of TAC, S571A mice decreased by less than 10% over the same period. These data indicate that phosphorylation at Ser571 contributes to development of heart failure but not hypertrophy in response to pressure
S571A animals displayed a small but significant increase in RR interval (Figure 4D
)
Phosphorylation of S571 contributes to myocardial remodeling following tra a ans ns nsao ao aort rt rtic ic ic constriction
Seve ve era ra ral l l st st stud ud udie ie i s ha ha hav v ve implicated both CaMKII and nd nd m I I I N Na,L I I I in maladaptive r re remo m m deling and ar ar arrh h hythmias in i a a ani n nima ma mal l l mo mo mode de dels ls ls o o of f f he he hear a a t t t fa ailur ur re. 6, 6 35--38 8 Th h her er eref ef efor or re, t t tra ra ans ns nsao ao aor rti ic co o ons ns nstr tr tric ic icti ti tion n n ( ( (TA TA TAC) C) C) wa wa as ut u u ilized d d t t to o o te e est t t the e e h h hypot t the he esi s s s th th that Se er e 57 7 71 serv ve e es a a as an a i i imp mp mpor r rta a ant nt t lo o ocu us l l lin in inki k k ng g g C C CaM MK K KII dy d dysr sr sreg eg egul l ulat at atio io ion n n to to to i i inc nc ncre re reas as ased ed ed I I I Na,L I a a and nd nd m m mal al alad ad adap ap apti ti tive e ve r r rem em emod od odel el elin in ing g g in in in r r res es espo po pons ns nse e e to to to p p pre re ress ss ssur r ure e e ov o over er erlo lo load ad ad overload.
In parallel, electrophysiology was performed to assess the role of Ser571 in TAC-induced electrical remodeling. While I Na,L was relatively small in WT myocytes at baseline (Figure 2B ), TAC resulted in a large I Na,L in WT comparable to that measured in S571E (Figure 6 ). In contrast, S571A myocytes were resistant to the increase in I Na,L observed in WT following 6 weeks of TAC. I Na,L was large in S571E at baseline and did not change significantly with TAC, presumably reflecting its near maximal value at baseline. Peak I Na was not different between TAC groups (Supplemental fo fo foll ll llow o owin in ing g g 6 6 6 we e week ek eks s s of of of T T TAC AC AC, in in indi di dica ca cati ti ting ng ng a a an n n an an anti ti ti a a -arr rr rrhy h hyth th thmi mi mic c c be be bene ne nefi fi fit t t fr fr from om om e e eli li limi mi mina na nati ti ting ng ng C C CaM aM aMKI KI KII I I TAC data indicate that phosphorylation at Ser571 is required for increased I Na,L , maladaptive remodeling, and arrhythmias, but not hypertrophy or CaMKII activation in response to pressure overload.
Discussion
As we consider progress in the field over the past 20 years, it is apparent that we have stagnated in our search for new anti-arrhythmia therapies. 39 The apparent impasse may be partly attributed to high profile failure of trials designed to test ion channels as anti-arrhythmia targets. 2, 40 While I Na,L inhibition has emerged as a candidate with therapeutic potential, the question remains: How do we target pathogenic components of ion channels or other targets without affecting components that are essential for normal physiology? In this study, we present a number of new findings that suggest it may be possible to specifically target pathogenic component of I Na (I Na,L ) without altering other properties (e.g. channel availability). Using two mouse models (S571E and S571A) that we anticipate will be useful to study the in vivo molecular mechanism for a wide range of cardiac disorders, we report that Ser571 is critically important for CaMKII-dependent regulation of I Na,L but not other channel properties linked to CaMKII (steady-state inactivation and recovery from inactivation). We also show that Ser571-mediated increases in I Na,L promote APD and QT prolongation and increase susceptibility to arrhythmia events at the cellular and organismal level. Finally, we demonstrate that Ser571 phosphorylation is required for maladaptive remodeling in response to pressure overload. Together, our results support CaMKIItargeted Ser571 as an important locus for specific control of I Na,L and identify a molecular pathway that may be manipulated for therapeutic advantage.
Growing evidence supports CaMKII as an important contributor to maladaptive do we target pathogenic components of ion channels or other targets without affect ct ctin in ing g g components that are essential for normal physiology? In this study, we present a number of new find din in ings gs gs t t tha ha hat t t sugg gg gge e est it may be possible to specif if fic ic ical a a ly target pathogenic ic c c c component of
w w with h hout alteri ing g g ot ther er er pr r rop op oper er erti ti tie es es ( ( (e. e.g. g g c c ch hann n nel el ava aila abil l lit it ity) y) y). U U Usin in ing g t tw two o o mo mo m use e e mo mo mode de dels ls l ( ( (S S S571 71 71E E E a a and S5 5 571 71 1A) A A that t t w we w a a an nt n icip ip pa at a e w w wil i i l l l be b b u u us s sefu fu ful l l to s s stu u udy t th h he in n n v v vivo o o m m mol ol olec ec ecul ul lar a m mech ha hani n n sm m m f f fo o or a a w w wide e e a a ang ng nge e e of of of c c car ar ardi di diac ac ac d d dis is isor or orde de ders rs rs, we e we r r rep ep epor or ort t t th th that at at S S Ser er er57 57 571 1 1 is is is c c cri ri riti ti tica ca call ll lly im im impo po port rt rtan an ant t t fo fo for r r Ca Ca CaMK MK MKII II II d d -dep ep epen en ende de dent nt nt remodeling and arrhythmias in a variety of cardiac disease states. 24 CaMKII dysregulation has also been shown to promote pathology in specific inherited arrhythmia syndromes. 22, [41] [42] [43] While efforts are underway to develop therapeutic compounds that target CaMKII, 44 it would be shortsighted to not consider alternative branches in the CaMKII signaling pathway as potential targets for therapy. I Na,L is one such target that has shown promise. The MERLIN-TIMI-36 trial tested arrhythmia therapy in acute coronary syndrome patients and showed that ranolazine decreased incidence of ventricular tachycardia without a significant effect on sudden death. 11 Ranolazine has also been evaluated for treatment of atrial fibrillation in both preclinical 15, 16 and clinical 17, 18 settings with additional trials underway. 19 While our studies focused on ventricular arrhythmias and remodeling, it will be interesting to determine whether phosphorylation at S571 alters electrophysiology/function in other heart regions (e.g. sinoatrial node, conduction system, atrium). Furthermore, aside from I Na,L or CaMKII, it is interesting to consider targeting upstream protein(s) responsible for organizing the relevant signaling domain (e.g. IV -spectrin and ankyrin-).
26, 33
Previous studies have reported both "gain-of-function" (increased I Na,L ) and "loss-offunction" (decreased availability) effects of CaMKII phosphorylation on I Na . 22, 25-27, 29 One possible explanation for this behavior is that a single molecular event (phosphorylation at a single residue) gives rise to complex changes in channel gating analogous to the 1795insD human arrhythmia mutation that produces long-QT at slow pacing but Brugada syndrome at fast pacing. 45 A second possibility is that the overall phenotype is the result of multiple phosphorylation events, which have distinct effects on channel behavior. 29, 30, 46, 47 Our unexpected finding that Ser571 regulates I Na,L but not other properties is consistent with the latter scenario and supports involvement for more than one site in determination of the overall and remodeling, it will be interesting to determine whether phosphorylation at S57 57 571 1 1 al al alte te ters rs rs electrophysiology/function in other heart regions (e.g. sinoatrial node, conduction system, atrium um um). ). ). Fu Fu Furt rt rtherm rm rmor o e, aside from I Na,L I I or CaMK K KII II II, it i is interesting to con on onsider targeting upstream p p prot t tein(s) respo o on ns n i ible le le for or or o o org rg rgan an ani iz izi i ing ng ng t t the h he rel el lev ev evan a t sig g gnal al alin in ing g do do doma ma main n n ( ( (e e.g g. g IV -s -s spe pe pect ct ctri ri rin n n an an and d d an n nky ky kyri r r n-).
26, 33 33 33 Pr Pr Prev e evio io ious s us s s stu t tudi di dies es es h h hav a ave e e re re repo po port rt rted ed ed b b bot ot oth h h " " "ga ga gain in in o o -of f f-fu f func nc ncti ti tion on on" " " (i (i (inc nc ncre re reas as ased ed ed I I I Na,L I I ) ) ) an an and d d "l "l "los os oss s s-of of of-phenotype. In fact, previous in vitro cell expression studies have identified a possible role for phosphorylation of residues Ser516 and Thr594 in mediating CaMKII-dependent regulation of I Na availability. 29 At the same time proteomics-based approaches in mouse 30 and human 47 have identified these (Ser571 and Ser516, specifically) and other sites in the DI-DII loop as potential phosphorylation sites for CaMKII. It is important to note that while our findings regarding the role of Ser571 in regulating I Na,L are consistent with previous in vitro studies, results on availability and recovery are divergent. 22, 29 This discrepancy may arise from differences in protocol inherent in the use of in vitro over-expression system (acute) compared to in vivo knock-in (chronic) strategy. It will be necessary going forward to determine whether phosphorylation at other sites 29, 30 may explain other aspects of the phenotype.
Our observation that ablation of the Ser571 site prevents TAC-induced increases in I Na,L ,
APD and arrhythmias is consistent with recent studies using ranolazine in pressure overloadinduced murine heart failure. 6 Specifically, it was shown that, similar to S571A, ranolazine treatment restored I Na,L and APD to baseline levels following TAC. Surprisingly, we did not find evidence that S571 phosphorylation had a significant effect on total or phosphorylated CaMKII in response to pressure overload. It will be important to determine whether a link between S571
and CaMKII expression/activation may be found in other animal models and/or disease states.
Our findings of the importance of Ser571 phosphorylation for maladaptive remodeling and heart failure in response to pressure-overload are also consistent with previous studies in CaMKII knockout animals. [35] [36] [37] These previous studies focused primarily on the role of CaMKIIdependent dysregulation of Ca 2+ handling in pathogenesis. While our studies support an involvement of increased I Na,L in heart failure, perhaps upstream of Ca 2+ handling defects, it is important to note that heart failure is a multifactorial disease that affects virtually every aspect of phosphorylation at other sites 29, 30 may explain other aspects of the phenotype.
Our observation that ablation of the Ser571 site prevents TAC-induced increases in I Na,L I I ,
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Limitations
While our findings provide insight into the mechanism linking Na v 1.5 phosphorylation, changes in I Na,L , remodeling and arrhythmias, we acknowledge multiple study limitations. First, the mouse is distinct from human with regards to its electrophysiology and cardiac function. 50 While AP, ion homeostasis and underlying ion currents vary greatly between mouse and larger animals, important electrophysiological features related to I Na,L are conserved across species.
Notably, the S571 site is conserved across species and I Na,L is detectable at baseline and increases with disease in mouse and larger animals. 3, 6, 21, 26 It is also important to note that while our studies indicate a role for S571 phosphorylation in controlling I Na,L , it remains unclear how S571 Notably, the S571 site is conserved across species and I Na,L I I is detectable at baseline and increases with h h d d dis is isea ea ease se se i i in mo mo mous u e and larger animals. 3, 6, 21, 26 It It It is also important to o o n n note that while our t t tud d dies indicate e e a a a r rol l le e e o fo or r r S5 S5 S571 71 71 p pho ho hosp s s ho h horyla la lati t o o on in n c c cont nt ntro ro roll ll llin in ing g g I I I N N Na,L L L I , it it it r r rem em e ains ns ns u u unc nc ncle le lear ar ar h h how w w S S S57 57 571 ph h hos os osph ph p orylat at atio i i n pr r rom m mot t tes in n ncre re reased ed ed I N N Na,L L L I . S S Sim m mila arl l ly, t t the he here e is s s so s s me me meue ue est tion n n ab ab about t w w why S571E E E an an anim im imal al als s s wi i with th th d d del el elay a ayed ed ed A A AP P P re re repo po pola la lari ri riza a zati ti tion on on a a and nd nd a a abn bn bnor or orma ma mal l l Ca Ca Ca 2+ Ta Ta Tabl bl ble e e 1 1 1. Ba Ba Base se seli li line ne ne e e ech ch choc oc ocar ar ardi di diog og ogra ra raph ph phic ic ic f f fea ea eatu t ture re res s s i i in n n WT WT WT, S5 S5 S571 71 71E E E an an and d d S5 S5 S571 71 71A A A mi mi mice ce ce. Representative AP traces from WT, S571E, and S571A ventricular myocytes following isoproterenol treatment (10 μM). Repolarization abnormalities (afterdepolarizations/repolarization failure) were apparent in S571E but not WT or S571A cells.
(E) Representative AP trace from S571E myocyte treated with isoproterenol followed by ranolazine treatment (1 μM), which eliminated isoproterenol-induced repolarization defects. 
SUPPLEMENTAL MATERIAL
Supplemental Methods
Histology: Hearts were fixed in neutral buffered 10% formalin, trimmed along the long axis to show both ventricles and both atria, processed routinely into paraffin, and then sectioned serially at 5 microns. Sections were stained using hematoxylin and eosin (H&E; to evaluate general organ structure and cell characteristics) and Masson's trichrome (to examine the amount of interstitial and perivascular fibrous connective tissue).
Biochemistry and immunostaining:
Equal quantities of ventricular lysates (determined using standard BCA protocols and verified through Ponceau stain of blots) were analyzed by SDS-PAGE and immunoblot, as described. [1] [2] [3] [4] Any remaining small differences in loaded protein levels were corrected by normalizing protein levels to GAPDH. Adult cardiomyocytes were isolated, immunostained, and imaged as described previously. Intracellular Ca 2+ measurements: Intracellular Ca 2+ cycling was monitored as described previously. 6 Briefly, cardiomyocytes were loaded with cytosolic Ca 
Supplemental Figure 8. (A) Summary densitometry data (mean±SEM) and (B)
representative immunoblots for phosphoand total CaMKII in WT, S571E, and S571A detergent-soluble heart lysates at baseline and following 6-week TAC. (P=NS, N=3 for WT, S571E and S571A baseline, N = 4 for WT TAC and S571A TAC, N=5 for S571E TAC).
